PFIZER: ‘Vaccine 100% Effective Against COVID-19 For Ages 12-15’

Sponsored

Crypto's Next "Trillion-Dollar" Coin?

In 2016, he recommended Bitcoin at $428... the World's First Trillion-Dollar Coin. Now he's sharing a free new recommendation... Learn More

Privacy Policy/Disclosures

A press release put out by Pfizer last Monday claimed strong results for the Pfizer-BioNTech COVID-19 shot, with the large pharmaceutical organization boldly claiming near-perfect efficacy and zero serious safety concerns whatsoever.

Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no serious safety concerns identified

Data will support planned submissions for full regulatory approval of the vaccine in this age group in the U.S. and worldwide

Pfizer press release

According to the report, there were “no serious safety concerns observed in individuals with at least 6 months of safety follow-up after the second dose.”

As far as the “100% efficacy” goes, there is a catch. Take a look at this statement by Pfizer.

The updated findings from the companies’ pivotal Phase 3 trial show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the second dose.

Pfizer press release

Pfizer themselves admitted that this data only follows a mere four months after the second dose. In other words, they offered no guarantees of the shot’s efficacy beyond that short time frame.

“As the global health community works to increase the number of vaccinated people around the world, these additional data provide further confidence in our vaccine’s safety and effectiveness profile in adolescents. This is especially important as we see rates of COVID-19 climbing in this age group in some regions, while vaccine uptake has slowed,” said Albert Bourla, Chairman and Chief Executive Officer of Pfizer. “We look forward to sharing these data with the FDA and other regulators.”

The CEO of BioNTech pointed out that the only data available on the alleged ‘safety’ and ‘efficacy’ of the shot stem from the Pfizer-conducted experiments themselves. Many have pondered if such a model is truly reliable, voicing concerns of a potential conflict of interest that could lead to the prioritization of profits over people.

“These are the first and only disclosed longer-term data demonstrating the safety and efficacy of a COVID-19 vaccine in individuals 12 through 15 years of age,” said Ugur Sahin, CEO and Co-founder of BioNTech. “The growing body of data we have compiled from clinical trials and real-world surveillance to date strengthen the base of evidence supporting the strong efficacy and favorable safety profile of our COVID-19 vaccine across adolescent and adult populations.”

Pfizer’s press release also stated that the findings of their experiment would make up the data that the Food and Drug Administration (FDA) would use for review to expand its approval from the Emergency Use Authorization (previously granted in May) to something more formal.

Big League Politics has previously reported on other statements by Pfizer and its executive leadership, including CEO Albert Bourla’s statement that people who spread misinformation on Covid-19 vaccines are “criminals” that have cost us “millions of lives.”

Support Big League Politics by making a donation today. You can also donate via PayPalVenmo or donate crypto. Your support helps us take on the powerful and report the truth that the mainstream media wants to silence. 

Sponsored

Man Who Predicted Bitcoin Says “This Is Bigger”

This technology could have an impact 113 times bigger than the internet… 600 times bigger than 5G… and 2,000 times bigger than Bitcoin. Learn More

Privacy Policy/Disclosures

Sponsored

Hidden Gems of Crypto

Weiss Ratings founder Martin Weiss names the hidden gems of a crypto sector that has grown 100-fold since 2020 and could grow another 400-fold in the months ahead. Plus, he gives you access to an early-bird, backdoor method for buying the gems of this sector for 80%, 90%, even 99% less than other investors will probably pay. Click here for all the details.

Privacy Policy/Disclosures